01672.HK
Ascletis Pharma Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 8.97
+10.13%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 8.41
From 52W high−53.16%
Volume4.63M
Market capHKD 8.72B
P/E (TTM)—
P/S (TTM)7877.9x
Div yield—
Key dataSep 18, 2026
Open
HKD 8.41
From 52W high
−53.16%
Volume
4.63M
Market cap
HKD 8.72B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.0x
P/E (TTM)
—
RSI (14)
42.6
MomentumView details →
1D Return
+10.13%
YTD Return
−21.25%
Similar companies
Latest newsMore news →
Hong Kong stocks closed higher on September 18, 2026, with the Hang Seng Index up 146 points (0.6%) at 24,750 and the Hang Seng Tech Index up 94 points (2.2%) at 4,405, as Alibaba rose over 3% and Lenovo Group, Liuliumei, Lenovo Holdings, Yingsheng Holdings and GenScript Biotech hit record highs.2d agoAscletis Pharma's ordinary shares were included in the eligible securities list of the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect (collectively 'Stock Connect'), effective from September 7, 2026, allowing eligible mainland Chinese investors to trade the shares.14d agoShanghai Stock Exchange announced adjustments to the Stock Connect southbound eligible securities, adding 54 stocks including Baidu and Ascletis Pharma, and removing 15 stocks including Youjia Innovation.16d ago